American Investment Services Inc. Acquires New Shares in Pfizer Inc. (NYSE:PFE)

American Investment Services Inc. purchased a new position in shares of Pfizer Inc. (NYSE:PFE - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 14,002 shares of the biopharmaceutical company's stock, valued at approximately $371,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. BridgePort Financial Solutions LLC acquired a new position in Pfizer in the fourth quarter valued at approximately $331,000. Park Square Financial Group LLC purchased a new position in Pfizer in the fourth quarter worth $128,000. QSM Asset Management Ltd purchased a new position in Pfizer in the fourth quarter worth $7,049,000. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in Pfizer in the fourth quarter worth $109,832,000. Finally, REAP Financial Group LLC raised its position in Pfizer by 81.1% in the fourth quarter. REAP Financial Group LLC now owns 1,405 shares of the biopharmaceutical company's stock worth $37,000 after acquiring an additional 629 shares in the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Trading Down 1.8%

NYSE:PFE traded down $0.43 during mid-day trading on Wednesday, reaching $23.18. The company's stock had a trading volume of 36,659,825 shares, compared to its average volume of 41,097,811. The company's fifty day simple moving average is $23.28 and its two-hundred day simple moving average is $25.12. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $31.54. The stock has a market cap of $131.79 billion, a P/E ratio of 16.44, a P/E/G ratio of 0.64 and a beta of 0.58.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. During the same period last year, the company earned $0.82 EPS. The firm's quarterly revenue was down 7.8% on a year-over-year basis. On average, equities analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, May 9th. This represents a $1.72 annualized dividend and a dividend yield of 7.42%. Pfizer's payout ratio is currently 124.64%.

Analysts Set New Price Targets

PFE has been the subject of several research analyst reports. UBS Group increased their price objective on Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 30th. Guggenheim reiterated a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. Citigroup reissued a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. Cantor Fitzgerald started coverage on Pfizer in a report on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 target price on the stock. Finally, The Goldman Sachs Group reissued a "neutral" rating and issued a $25.00 target price (down previously from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, four have assigned a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, Pfizer presently has an average rating of "Moderate Buy" and a consensus price target of $29.17.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.